Clinical Trials Logo

Progress-free Survival clinical trials

View clinical trials related to Progress-free Survival.

Filter by:
  • None
  • Page 1

NCT ID: NCT01291667 Completed - Adverse Events Clinical Trials

Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE

HOPES
Start date: May 2009
Phase: Phase 3
Study type: Observational

Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China. Trastuzumab has been proved valuable treatment for HER2-positive breast cancer patients. Cipterbin® is developing by Shanghai CP Guojian Pharmaceutical Co.Ltd.Now we carried on the phase III trial in order to prove Cipterbin® 's efficacy and safety.